Pennington Partners & Co’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$742K Sell
642
-39
-6% -$46K 0.24% 51
2026
Q2
$817K Sell
681
-53
-7% -$54.2K 0.26% 49
2026
Q1
$675K Buy
734
+479
+188% +$486K 0.23% 53
2025
Q4
$274K Buy
+255
New +$244K 0.11% 79
2025
Q2
– Sell
-315
Closed -$260K – 85
2025
Q1
$260K Sell
315
-265
-46% -$221K 0.15% 64
2024
Q4
$448K Buy
+580
New +$480K 0.22% 50

Other funds holding LLY

Pennington Partners & Co's LLY Position: Q3 2026 in Review

Pennington Partners & Co reduced its Eli Lilly (LLY) stake by 5.7% in Q3 2026, selling an estimated $46K and leaving 642 shares worth $742K. The position accounts for 0.24% of the portfolio, ranked #51.

Pennington Partners & Co first reported a position in LLY in Q4 2024 and has held it in 6 quarters since. The position peaked at $817K in Q2 2026. 4,590 funds tracked by Wall St. Rank hold LLY as of Q3 2026.

  • Pennington Partners & Co held 642 shares of Eli Lilly worth $742K as of Q3 2026.
  • Pennington Partners & Co sold 39 Eli Lilly shares in Q3 2026, an estimated $46K.
  • Eli Lilly made up 0.24% of Pennington Partners & Co's portfolio in Q3 2026, its #51 holding.
  • Pennington Partners & Co first reported a position in Eli Lilly in Q4 2024 and has held it in 6 quarters since.
  • Pennington Partners & Co's Eli Lilly position peaked at $817K in Q2 2026.
  • 4,590 funds tracked by Wall St. Rank held Eli Lilly as of Q3 2026.

Based on Pennington Partners & Co's 13F filing for Q3 2026, filed 13 Nov 2026.